# Sarepta Therapeutics, Inc.: filings

SRPT · Nasdaq · CIK 873303 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srpt.md) · [Financials](/companies/srpt/financials.md) · [Filings](/companies/srpt/filings.md) · [Insiders](/companies/srpt/insiders.md)

## Reports and events: 345 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 504, 8-K 237, SC 13G/A 60, 10-Q 53, 3 49, 424B5 24, SC 13G 24, 10-K 18, CT ORDER 18, DEF 14A 18, 144 17, S-8 16, CORRESP 15, UPLOAD 14, 4/A 13, DEFA14A 11, SCHEDULE 13G/A 10, S-8 POS 7, PRE 14A 6, S-3ASR 6, 10-K/A 5, ARS 5, SC 13D/A 4, SCHEDULE 13G 4, 13F-HR 3, 8-K/A 3, EFFECT 3, SC 13D 3, 10-Q/A 2, 5 2, D 2, FWP 2, POS AM 2, POSASR 2, S-3 2, 3/A 1, 424B3 1, 8-K12B 1, SCHEDULE 13D 1, SCHEDULE 13D/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:06 ET | [8-K](/filings/0001193125-26-335056.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335056 |
| 2026-08-05 | 16:01 ET | [10-Q](/filings/0001193125-26-335003.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335003 |
| 2026-07-27 | 09:08 ET | [8-K](/filings/0001193125-26-316995.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-316995 |
| 2026-06-04 | 16:29 ET | [8-K](/filings/0001193125-26-257501.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257501 |
| 2026-05-06 | 16:10 ET | [8-K](/filings/0001193125-26-208966.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208966 |
| 2026-05-06 | 16:01 ET | [10-Q](/filings/0001193125-26-208893.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208893 |
| 2026-04-24 | 16:10 ET | [DEF 14A](/filings/0001193125-26-177247.md) | Proxy statement, period 2026-06-04 | 0001193125-26-177247 |
| 2026-03-02 | 07:02 ET | [10-K](/filings/0001193125-26-084144.md) | Annual report, period 2025-12-31 | 0001193125-26-084144 |
| 2026-02-25 | 17:09 ET | [8-K](/filings/0001193125-26-072064.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-072064 |
| 2026-02-25 | 16:10 ET | [8-K](/filings/0001193125-26-071566.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071566 |
| 2026-01-12 | 12:05 ET | [8-K](/filings/0001193125-26-010116.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-010116 |
| 2025-12-19 | 16:34 ET | [8-K](/filings/0001193125-25-326969.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-326969 |
| 2025-12-11 | 07:13 ET | [8-K](/filings/0001193125-25-315032.md) | 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-315032 |
| 2025-12-08 | 07:33 ET | [8-K](/filings/0001193125-25-310588.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-310588 |
| 2025-11-06 | 16:02 ET | [10-Q](/filings/0001193125-25-269436.md) | Quarterly report, period 2025-09-30 | 0001193125-25-269436 |
| 2025-11-03 | 16:18 ET | [8-K](/filings/0001193125-25-262591.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-262591 |
| 2025-08-29 | 16:18 ET | [8-K](/filings/0001193125-25-192794.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-192794 |
| 2025-08-21 | 07:07 ET | [8-K](/filings/0001193125-25-184625.md) | 3.02 Unregistered sale of equity | 0001193125-25-184625 |
| 2025-08-15 | 17:28 ET | [SCHEDULE 13D/A](/filings/0000950170-25-109461.md) | Ownership report, active investor, amended | 0000950170-25-109461 |
| 2025-08-13 | 16:10 ET | [8-K](/filings/0001193125-25-179819.md) | 5.02 Departure or appointment of officers or directors | 0001193125-25-179819 |
| 2025-08-06 | 16:02 ET | [10-Q](/filings/0000950170-25-103971.md) | Quarterly report, period 2025-06-30 | 0000950170-25-103971 |
| 2025-07-21 | 07:30 ET | [8-K](/filings/0001193125-25-161516.md) | 8.01 Other events | 0001193125-25-161516 |
| 2025-07-16 | 16:11 ET | [8-K](/filings/0000950170-25-096257.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-096257 |
| 2025-06-06 | 16:30 ET | [8-K](/filings/0000950170-25-083131.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-083131 |
| 2025-05-06 | 16:01 ET | [10-Q](/filings/0000950170-25-064412.md) | Quarterly report, period 2025-03-31 | 0000950170-25-064412 |
| 2025-04-24 | 16:05 ET | [DEF 14A](/filings/0000950170-25-058003.md) | Proxy statement, period 2025-06-05 | 0000950170-25-058003 |
| 2025-02-28 | 16:01 ET | [10-K](/filings/0000950170-25-029973.md) | Annual report, period 2024-12-31 | 0000950170-25-029973 |
| 2025-02-26 | 16:05 ET | [8-K](/filings/0000950170-25-027717.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-027717 |
| 2025-02-14 | 17:23 ET | [SCHEDULE 13D](/filings/0000950170-25-021481.md) | Ownership report, active investor | 0000950170-25-021481 |
| 2025-02-14 | 08:38 ET | [8-K](/filings/0001193125-25-026683.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-026683 |
| 2025-01-13 | 12:25 ET | [8-K](/filings/0001193125-25-005160.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-005160 |
| 2024-11-26 | 07:17 ET | [8-K](/filings/0001193125-24-265627.md) | 1.01 Entry into a material agreement | 0001193125-24-265627 |
| 2024-11-06 | 16:01 ET | [10-Q](/filings/0000950170-24-122239.md) | Quarterly report, period 2024-09-30 | 0000950170-24-122239 |
| 2024-09-16 | 08:51 ET | [8-K](/filings/0000950170-24-106619.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-24-106619 |
| 2024-08-07 | 16:01 ET | [10-Q](/filings/0000950170-24-092720.md) | Quarterly report, period 2024-06-30 | 0000950170-24-092720 |
| 2024-06-07 | 16:45 ET | [8-K](/filings/0001193125-24-157458.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-157458 |
| 2024-05-01 | 16:01 ET | [10-Q](/filings/0000950170-24-051234.md) | Quarterly report, period 2024-03-31 | 0000950170-24-051234 |
| 2024-04-24 | 16:05 ET | [DEF 14A](/filings/0000950170-24-047570.md) | Proxy statement, period 2024-06-06 | 0000950170-24-047570 |
| 2024-02-28 | 16:01 ET | [10-K](/filings/0000950170-24-022036.md) | Annual report, period 2023-12-31 | 0000950170-24-022036 |
| 2024-01-08 | 12:08 ET | [8-K](/filings/0000950170-24-002822.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-002822 |
| 2023-11-01 | 16:01 ET | [10-Q](/filings/0000950170-23-057414.md) | Quarterly report, period 2023-09-30 | 0000950170-23-057414 |
| 2023-08-02 | 16:02 ET | [10-Q](/filings/0000950170-23-037125.md) | Quarterly report, period 2023-06-30 | 0000950170-23-037125 |
| 2023-06-22 | 16:49 ET | [8-K](/filings/0000950170-23-029438.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-029438 |
| 2023-06-22 | 14:22 ET | [8-K](/filings/0000950170-23-029354.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-029354 |
| 2023-06-09 | 16:29 ET | [8-K](/filings/0000950170-23-027276.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-23-027276 |
| 2023-05-02 | 16:02 ET | [10-Q](/filings/0000950170-23-016654.md) | Quarterly report, period 2023-03-31 | 0000950170-23-016654 |
| 2023-04-24 | 16:08 ET | [DEF 14A](/filings/0000950170-23-014085.md) | Proxy statement | 0000950170-23-014085 |
| 2023-03-03 | 07:31 ET | [8-K](/filings/0001193125-23-058990.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-23-058990 |
| 2023-02-28 | 16:04 ET | [10-K](/filings/0000950170-23-005062.md) | Annual report, period 2022-12-31 | 0000950170-23-005062 |
| 2023-01-09 | 13:40 ET | [8-K](/filings/0000950170-23-000495.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-000495 |

Page 1 of 7. [Older](/companies/srpt/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:58 ET. No prices; not investment advice.